Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This study evaluated the cost-effectiveness of bevifibatide versus eptifibatide for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) in China. A 30-day decision tree and 15-year Markov model simulated outcomes using matching-adjusted indirect comparison data. Base-case analysis used current listed price of bevifibatide (¥1290/vial). Costs and quality-adjusted life-years (QALYs) were evaluated against willingness-to-pay (WTP) thresholds based on China's per capita gross domestic product (GDP). Base-case results showed bevifibatide added ¥12,909.24 and 0.0595 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of ¥216,899/QALY. This significantly exceeds the ¥76,599 WTP threshold (0.8 times GDP), indicating it is not cost-effective. Lifetime analysis confirmed these results (ICER: ¥159,541/QALY). Threshold analysis indicated a price reduction to approximately ¥595/vial is required to achieve cost-effectiveness. In conclusion, bevifibatide is not cost-effective for ACS patients undergoing PCI in China at its current price. A substantial price reduction is necessary to align cost with clinical value, providing an evidence-based threshold for future reimbursement negotiations.
Fields of Study & Subjects
Health Systems
Economic Evaluations
Quality of Life
Coronary Interventions and Diagnostics
Antiplatelet Therapy and Cardiovascular Diseases
Publication details
- Journal / source
- Pharmacoeconomics and Policy
- Volume
- 2
- Issue
- 1
- Pages
- 46–53
- Publication date
- 1 March 2026
- Language
- EN